Does the presence of hepatitis virus B and C influence the evolution of diffuse large B-cell lymphoma?

Leukemia and Lymphoma

Volumn 56, Issue 6, 2015, Pages 1686-1690

  Rubio, Judit ^a   Franco, Fernando ^a   Sánchez, Antonio ^a   Cantos, Blanca ^a   Méndez, Miriam ^a   Calvo, Virginia ^a   Maximiano, Constanza ^a   Perez, David ^a   Millán, Isabel ^a   Sánchez Beato, Margarita ^a   Provencio, Mariano ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

Diffuse large B cell lymphoma; HBV reactivation; HCV reactivation; Hepatitis B; Hepatitis C

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LARGE CELL LYMPHOMA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; ADOLESCENT; DISEASE FREE SURVIVAL; HEPACIVIRUS; ISOLATION AND PURIFICATION; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; MORTALITY; PHYSIOLOGY; SURVIVAL RATE; VERY ELDERLY; VIROLOGY; VIRUS ACTIVATION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; HEPACIVIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL RATE; VIRUS ACTIVATION; YOUNG ADULT;

EID: 84932135676     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.963576     Document Type: Article

References (32)

1. Swerdlow SH, Campo E, Harris NL, et al, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008.
2. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-511.
3. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937-1947.
4. Czuczman M S, Grillo-Lopez A J, White C A, et al. T reatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17: 268-276.
5. Engels EA, Cho E R, Jee S H. H epatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: A cohort study. Lancet Oncol 2010; 11: 827-834.
6. Gisbert JP, Garcí a-Buey L, Pajares JM, et al. Prevalence of hepatitis C virus infection in B-cell non-Hodgkin ' s lymphoma: systematic review and meta- Analysis. Gastroenterology 2003; 125: 1723-1732.
7. Mele A, Pulsoni A, Bianco E, et al. Hepatitis C virus and B-cell non-Hodgkin lymphomas: An Italian multi-center case-control study. Blood 2003; 102: 996-999.
8. Luppi M, Longo G, Ferrari M G, et al. A dditional neoplasms and HCV infection in low-grade lymphoma of MALT type. Br J Haematol 1996; 94: 373-375.
9. De Vita S, Sacco C, Sansonno D, et al. Characterization of overt B-cell lymphomas in patients with hepatitis C virus infection. Blood 1997; 90: 776-782.
10. Agnello V, Chung R T, Kaplan L M. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992; 327: 1490-1495.
11. Andreone P, Gramenzi A, Cursaro C, et al. Monoclonal gammopathy in patients with chronic hepatitis C virus infection. Blood 1996; 88: 1122.
12. Ferri C, Caracciolo F, Zignego AL, et al. Hepatitis C virus infection in patients with non-Hodgkin ' s lymphoma. Br J Haematol 1994; 88: 392-394.
13. Germanidis G, Haioun C, Dhumeaux D, et al. H epatitis C virus infection, mixed cryoglobulinemia, and B-cell non-Hodgkin ' s lymphoma. Hepatology 1999; 30: 822-823.
14. Cvetkovic R S, Perry C M. R ituximab: A review of its use in non-Hodgkin ' s lymphoma and chronic lymphocytic leukaemia. Drugs 2006; 66: 791-820.
15. Perceau G, Diris N, Estines O, et al. Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma. Br J Dermatol 2006; 155: 1053-1056.
16. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001; 344: 68-69.
17. Sera T, Hiasa Y, Michitaka K, et al. A nti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. Intern Med 2006; 45: 721-724.
18. Tsutsumi Y, Kawamura T, Saitoh S, et al. Hepatitis B virus reactivation in a case of non-Hodgkin ' s lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy. Leuk Lymphoma 2004; 45: 627-629.
19. Kusumoto S, Tanaka Y, Mizokami M, et al. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol 2009; 90: 13-23.
20. WesthoffTH, Jochimsen F, Schmittel A, et al. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 2003; 102: 1930.
21. Law JK, Ho JK, Hoskins PJ, et al. Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigennegative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma 2005; 46: 1085-1089.
22. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Biological agents. Volume 100 B. A review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum 2012; 100: 1-441.
23. Suarez F, Lortholary O, Hermine O, et al. I nfection associated lymphomas derived from marginal zone B cells: A model of antigendriven lymphoproliferation. Blood 2006; 107: 3034-3044.
24. Besson C, Canioni D, Lepage E, et al. Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d ' Etude des Lymphomes del ' Adulte Programs. J Clin Oncol 2006; 24: 953-960.
25. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107.
26. Yeo W, Chan P, Zhong S, et al. F requency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors. J Med Virol 2000; 62: 299-307.
27. Hoofnagle J. Reactivation of Hepatitis B. Hepatology 2009; 49(Suppl. 5): S156-S165.
28. Sanchez MJ, Buti M, Homs M, et al. Successful use of entecavir for a severe a case of reactivation of hepatits B virus following polychemotherapy containing rituximab. J Hepatol 2009; 51: 1091-1096.
29. Colson P, Borentain P, Cose D, et al. Entecavir as afirst line treatment for HBV reactivation following polychemotherapy for lymphoma. Br J Haematol 2008; 143: 148-150.
30. Mahale P, Kontoyiannis DP, Chemaly RF, et al. Acute exacerbation and viral reactivation of chronic hepatitis C infection in cancer patients. J Hepatol 2012; 57: 1177-1185.
31. Torres HA, Davila M. Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat Rev Clin Oncol 2012; 9: 156-166.
32. Mahale P, Okhuysen PC, Torres HA. Does chemotherapy cause viral relapse in cancer patients with hepatitis C infection successfully treated with antivirals? Clin Gastroenterol Hepatol 2014; 12: 1051-1054.e1